Invesco
NMTR

Invesco’s 9 Meters Biopharma NMTR Stock Holding History

Invesco’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,786
Closed -$45K – 4194
2022
Q1 		$45K Sell
3,786
-87
-2% -$1.19K ﹤0.01% 3938
2021
Q4 		$76K Sell
3,873
-5
-0.1% -$112 ﹤0.01% 3934
2021
Q3 		$101K Buy
3,878
+1,032
+36% +$24.3K ﹤0.01% 3941
2021
Q2 		$63K Buy
+2,846
New +$69.9K ﹤0.01% 3935

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWM
Curi Wealth Management Raleigh, North Carolina $724M AUM 17.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Invesco's NMTR Position: Q2 2022 in Review

Invesco sold out of 9 Meters Biopharma (NMTR) in Q2 2022, closing a stake of 3,786 shares — an estimated $45K sold.

Invesco first reported a position in NMTR in Q2 2021 and held it in 4 quarters. The position peaked at $101K in Q3 2021. 88 funds tracked by Wall St. Rank hold NMTR as of Q2 2022.

  • Invesco reported no remaining 9 Meters Biopharma position as of Q2 2022 after selling out during the quarter.
  • Invesco sold 3,786 9 Meters Biopharma shares in Q2 2022, an estimated $45K.
  • Invesco first reported a position in 9 Meters Biopharma in Q2 2021 and held it in 4 quarters.
  • Invesco's 9 Meters Biopharma position peaked at $101K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.